文献速递头颈与中枢神经肿瘤

基于转录组学的基因特征预测局部晚期鼻咽癌远处转移并指导诱导化疗的建立与验证

Development and validation of a transcriptomics-based gene signature to predict distant metastasis and guide induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
PubMed 文献 · Eur J Cancer · 2022-01-13

研究对12对转移风险不同的鼻咽癌活检样本行转录组测序,筛选出4个基因(AK4、CPAMD8、DDAH1、CRTR1)构建转移风险基因特征,在训练队列(n=191)和外部验证队列(n=263)中验证其预测远处转移和指导诱导化疗的能力。该特征可有效区分低危和高危转移组,低危患者从诱导化疗联合同步放化疗中获益,而高危患者未获益。

要点

  • 4基因特征可区分低危和高危转移组,训练队列C-index=0.752,验证队列C-index=0.741。
  • 低危组接受诱导化疗联合同步放化疗改善无远处转移生存(94.4% vs 85.0%,p=0.043)。
  • 高危组未从诱导化疗中获益(72.6% vs 74.9%,p=0.946)。

核心结论

  • 基于转录组学的基因特征能可靠预测局部晚期鼻咽癌的转移,并可识别可能从诱导化疗联合同步放化疗中获益的候选患者。

研究设计与样本

  • 对12对转移风险不同的鼻咽癌活检样本行转录组测序,用生物信息学和qPCR识别差异表达基因,用单因素和多因素分析筛选预后指标。
  • 在训练队列(n=191)中建立基于基因特征的列线图,并在外部队列(n=263)中验证。

主要发现

  • 在转移与非转移鼻咽癌间识别出11个差异表达基因,其中4个(AK4、CPAMD8、DDAH1和CRTR1)用于构建基因特征。
  • 基因特征将患者分为低危和高危转移组:训练队列低危组91.1% vs 高危组70.4%(p<0.0001,C-index=0.752)。
  • 验证队列低危组88.4% vs 高危组73.9%(p=0.00057,C-index=0.741)。
  • 低危患者接受诱导化疗联合同步放化疗改善无远处转移生存(94.4% vs 85.0%,p=0.043)。
  • 高危患者未从诱导化疗中获益(72.6% vs 74.9%,p=0.946)。

关键数值与推荐

  • 基因特征包含4个基因:AK4、CPAMD8、DDAH1和CRTR1。
  • 训练队列低危组91.1% vs 高危组70.4%(p<0.0001,C-index=0.752)。
  • 验证队列低危组88.4% vs 高危组73.9%(p=0.00057,C-index=0.741)。
  • 低危组诱导化疗联合同步放化疗 vs 未联合:无远处转移生存94.4% vs 85.0%(p=0.043)。
  • 高危组诱导化疗联合同步放化疗 vs 未联合:无远处转移生存72.6% vs 74.9%(p=0.946)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Metastasis is the primary cause of treatment failure in nasopharyngeal carcinoma (NPC); however, the current tumour-node-metastasis staging system has limitations in predicting distant metastasis and guiding induction chemotherapy (IC) application. Here, we established a transcriptomics-based gene signature to assess the risk of distant metastasis and guide IC in locoregionally advanced NPC. METHODS: Transcriptome sequencing was performed on NPC biopsy samples from 12 pairs of patients with different metastasis risks. Bioinformatics and qPCR were used to identify differentially expressed genes (DEGs), while univariate and multivariate analyses were used to select prognostic indicators for the gene signature. A signature-based nomogram was established in a training cohort (n = 191) and validated in an external cohort (n = 263). RESULTS: Eleven DEGs were identified between metastatic and non-metastatic NPC. Four of these (AK4, CPAMD8, DDAH1 and CRTR1) were used to create a gene signature that effectively categorised patients into low- and high-risk metastasis groups (training: 91.1 versus 70.4%, p < 0.0001, C-index = 0.752; validation: 88.4 versus 73.9%, p = 0.00057, C-index = 0.741). IC with concurrent chemoradiotherapy (CCRT) improved distant metastasis-free survival in low-risk patients (94.4 versus 85.0%, p = 0.043), whereas patients in the high-risk group did not benefit from IC (72.6 versus 74.9%, p = 0.946). CONCLUSIONS: Our transcriptomics-based gene signature was able to reliably predict metastasis in locoregionally advanced NPC and could be used to identify candidates that could benefit from IC + CCRT.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Liu SL, Sun XS, Chen QY, et al. Development and validation of a transcriptomics-based gene signature to predict distant metastasis and guide induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Eur J Cancer. 2022. PMID: 35032814. doi:10.1016/j.ejca.2021.12.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。